Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Seasonal Allergic Rhinitis (SAR)

UCB Pharma0 个研究点目标入组 67 人开始时间: 2003年8月最近更新: 2013年12月16日

适应症

试验速览

To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis

•Male or female, 18 to 60 years old, inclusive
•two-year history of allergic rhinitis due to tree, grass or weed pollen
•sufficient histamine-dependent symptoms of rhinitis during the selection week (T5SS ≥ 5)

•An ear, nose or throat (ENT) infection
•asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn
•atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment
•an associated ENT disease
•use of decongestants
•nasal or ocular topical treatment

Investigator rated T5SS (Total 5 symptom Score) over 2 weeks

时间窗: 2 weeks

Investigator's global efficacy evaluation at 2 weeks; the patient's mean T5SS and 5 individual symptoms (over the last 24 hours) over the first week and over the 2 weeks of treatment; the Symptoms Score Reducing Index (SSRI).(2 weeks)

发起方

申办方类型

Industry